Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric hepatitis C

Executive Summary

Pediatric Subcommittee of FDA's Anti-Infective Drugs Advisory Committee will discuss drug development for pediatric patients with chronic hepatitis C on April 23. FDA will also present an update on efforts to ensure adequate labeling and proper pediatric use of therapies during the meeting. On April 24, the committee will discuss clinical trial design for antimuscarinics to control drooling in children with cerebral palsy and other neurological diseases as well as ethical issues for performing studies in children with special needs. The meeting will begin at 8 a.m. both days at the CDER advisory committee conference room, 5630 Fishers Lane, Rockville, Md
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS037520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel